芳香化酶抑制剂在卵巢癌治疗中的作用

Aromatase inhibitors in the treatment of ovarian cancer

芳香化酶抑制剂(aromatase inhibitors,ARI)是一组通过抑制芳香化酶(aromatase,AR)活性,阻断内源性雌激素合成以使雌激素水平下降,从而达到治疗雌激素依赖性肿瘤生长的药物。主要用于绝经后雌激素受体(estrogen receptor,ER)阳性乳腺癌患者的辅助治疗。近年来,越来越多的证据表明雌激素可能参与了卵巢癌的发生与发展,抗雌激素治疗对卵巢癌,尤其在难治性、复发性卵巢癌的二、三线治疗中具有一定效果,文中就此作一综述。

The aromatase inhibitor（ARI） is an estrogen synthesis blocker by inhibiting aromatase（AR） activity,which is mainly used in the treatment of estrogen receptor（ER） positive breast cancer in postmenopausal women.There is growing clinical and experimental evidence that estrogen may play a role in ovarian tumorigenesis and tumor progression.Anti-aromatase therapy has been shown to be a beneficial profile for recurrent refractory ovarian cancer.